摘要
1例58岁男性患者,既往有高血压、糖尿病病史,因"确诊肺腺鳞癌2个月"入院。入院后完善相关检查,患者血常规和血生化正常,给予吉西他滨(1.8 g,d1,d8)+重组人血管内皮抑制素(30 mg,d1-7)+卡铂(0.4 g,d1),同时给予护肝、护胃和止吐等对症治疗。临床药师结合诊治指南并与医生积极沟通,应关注重组人血管内皮抑制素注射液的使用剂量及疗程,同时在化疗期间应密切监测患者的血常规、生化指标,并对患者进行用药教育。治疗期间,患者并未出现不适症状,嘱其出院后定期复查、随访。
One 58-year-male patient had a history of hypertension and diabetes mellitus,and was admitted to the hospital for 2 months after the diagnosis of pulmonary squamous cell carcinoma.The patient’s blood routine and blood biochemistry were normal,the patient was given gemcitabine（1.8 g,d1,d8） ＋ recombinant human endostatin（30 mg,d1-7） and carboplatin（0.4 g,d1） including liver-protecting,stomach-protecting,antiemetic and other symptomatic treatment.According to guidelines,clinical pharmacists communicated with the doctor actively,and suggested paying attention to the dose and treatment course of recombinant human endostatin,and close monitoring of the patient’s blood routine,biochemical indexes during the chemotherapy and medication education for patients.During the period of treatment,the patient showed no symptoms of discomfort.The patient was ordered to review and follow up regularly after discharge.
出处
《中国药物应用与监测》
CAS
2017年第6期343-346,共4页
Chinese Journal of Drug Application and Monitoring
基金
解放军总医院临床科研扶持基金项目(2016FCCXYY-2014)
